Class: Use (276)
Genome mutation by intron insertion into an embryonic stem cell genome
Patent Number: 7,205,148Genetic manipulation of ES cells provides a powerful method for developing unique cell line models of various human diseases. More clinically applicable is the possibility of specifically producing mutations in genes that elicit rejection of ES cells, so as to generate "universal donor" stem cells. This patent teaches ways of generating mutations in exons of genes in ES cells by...
Transgenic pigs carrying both hHO-1 and hDAF transgenes for xenotransplantation
Patent Number: 7,378,569Xenotransplantation offers the possibility of using animal organs either permanently as a substitute for human organs, or as a "bridge" until a suitable human organ may be found. The most significant barriers to xenotransplantation appear to be innate in nature. Specifically, the first barrier is the hyperacute rejection, which occurs because of a very high level of...
Reduction of dermal scarring
Patent Number: 7,465,442TGF-beta is a multi-functioning cytokine with activities in a variety of physiological processes, including suppression of inflammation, protecting the bone marrow from stress, and stimulation of fibrosis. TGF-beta is known to inhibit cell cycle progression in part by turning on...
Methods of recruiting fibroblasts by administering G-CSF
Patent Number: 7,531,510Recruitment of various progenitor cells into injured tissue is a well known phenomena. For example, after infarct, mobilization of bone marrow stem cells into the injured myocardium has been reported. The current patent uses G-CSF, a cytokine that stimulates hematopoiesis and causes
1 Comment
Myocardial stimulation
Patent Number: 7,349,740The positive effects of stem cells in cardiac conditions is supported by many clinical trials. Efficacy has been demonstrated by both intracoronary administration, as well as intravenous administration of bone marrow and mesenchymal stem cells, respectively.
In this patent, Medronics was granted some pretty far-reaching claims. This is a representative claim
"A...
Treatment of retinitis pigmentosa with human umbilical cord cells
Patent Number: 7,413,734Classically cord blood transplantation is used for the treatment of hematological disorders in which the recipient hematopoietic stem cell compartment is ablated (by chemotherapy and/or radiation) and the donor cord blood cells are used for hematopoietic rescue. However the use of cord blood in the area of regenerative medicine (non-hematopoietic purposes) does not require destruction...
Soft tissue repair and regeneration using postpartum-derived cells
Patent Number: 7,560,276Despite the fact the Celgene through Bob Hariri owns the majority of the placental tissue cells, this patent, assigned to Ethicon, seems to circumvent some of the Celgene claims and covers use of CD117 negative cells from placenta for wound healing.
The patent covers a method of stimulating soft tissue infiltration in a tissue defect by adding...
Modulation of C-reactive protein expression
Patent Number: 7,425,545Inflammatory mediators are known to attract stem cells in acute settings, and inhibit stem cells in chronic settings. For example, in stroke patients, there is an increase in SDF-1, which is believed to account for mobilization of stem cells from the bone marrow into systemic circulation, and from there, presumably into the brain, where they mediate trophic...
Methods and compositions for nerve regeneration
Patent Number: 7,374,760Stem cell therapy has successfully been used in various animal models of neurodegenerative diseases including cerebral palsy, demyelinating conditions, and ALS. Stem cells in many situations do not need to differentiate into the cell of therapeutic interest to mediate effects but may simply provide...
Compositions for allogeneic cell therapy
Patent Number: 7,435,592This patent covers a composition of activated T cells, either autologous or allogeneic. It is very interesting since the way the claims issued, it covers pretty much any T cell that has been activated by ligation of CD3 and CD28 (the most common way of activating T cell cells).
The first independent claim covers a composition of T cells that are contacted with antibodies...